Page last updated: 2024-11-06

lm 985

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

LM 985: structure given in first source; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID55750
CHEMBL ID188797
MeSH IDM0140544

Synonyms (30)

Synonym
87626-56-0
lm-985
oxo-4-phenyl-2,4,h-1-benzopyran-8-yl 2-diethylaminoethyl acetate hcl
unii-3mqu39g359
3mqu39g359 ,
flavone acetic acid diethanolamine ester
lm 985
4h-1-benzopyran-8-acetic acid, 4-oxo-2-phenyl-, 2-(diethylamino)ethyl ester
NCI60_002422
NCIMECH_000531 ,
4h-1-benzopyran-8-acetic acid, 4-oxo-2-phenyl-, 2-(diethylamino)ethyl ester-
2-(diethylamino)ethyl (4-oxo-2-phenyl-4h-chromen-8-yl)acetate
2-diethylaminoethyl 2-(4-oxo-2-phenyl-chromen-8-yl)acetate
4h-1-benzopyran-8-acetic acid, 4-oxo-2-phenyl-, 2-(diethylamino)ethyl ester,hydrochloride
diethyl-{2-[2-(4-oxo-2-phenyl-4h-chromen-8-yl)-acetoxy]-ethyl}-ammonium
bdbm50154469
CHEMBL188797 ,
nci-293015
CCG-35538
lm985
2-(diethylamino)ethyl (4-oxo-2-phenyl-4h-chromen-8-yl)acetate #
ZMLZQKCBYPEYMG-UHFFFAOYSA-N
mitoflaxone 2-(diethylamino)ethyl ester
HY-U00379
CS-7450
2-(diethylamino)ethyl 2-(4-oxo-2-phenyl-4h-chromen-8-yl)acetate
DTXSID601007706
2-(diethylamino)ethyl (4-oxo-2-phenyl-4h-1-benzopyran-8-yl)acetate
2-(diethylamino)ethyl 2-(4-oxo-2-phenylchromen-8-yl)acetate
AKOS040741963

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic and in vitro drug degradation studies imply that the ester LM985 is hydrolyzed to LM975 (flavone acetic acid) rapidly in vivo."( Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester).
Cassidy, J; Cunningham, D; Forrest, G; Graham, J; Harding, M; Kaye, SB; Kerr, DJ; McGrath, JC; Setanoians, A; Vezin, WR, 1986
)
0.27
" Pharmacokinetic studies confirm the rapid degradation of LM985 to LM975, the possible active principle."( Pharmacokinetics and anti-tumour activity of LM985 in mice bearing transplantable adenocarcinomas of the colon.
Bibby, MC; Double, JA; Loadman, PM, 1986
)
0.27

Dosage Studied

ExcerptRelevanceReference
" Patients were treated at 14 dosage levels ranging from 10 to 1500 mg/m2."( Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester).
Cassidy, J; Cunningham, D; Forrest, G; Graham, J; Harding, M; Kaye, SB; Kerr, DJ; McGrath, JC; Setanoians, A; Vezin, WR, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)8.70000.00002.015110.0000AID240619
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID240619Inhibitory concentration against cytochrome P450 2D62004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (75.00)18.7374
1990's1 (12.50)18.2507
2000's1 (12.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.98 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]